Piper Sandler analyst Christopher Donat maintains American Express (NYSE:AXP) with a Overweight and lowers the price target from $202 to $163.
Paratek Pharmaceuticals Announces Top Line Data From Pilot Efficacy Study For The Treatment Of Pulmonary Anthrax And Acceptance Of The Second Procurement Of NUZYRA Under BARDA Project BioShield
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced positive top line data from a pilot rabbit efficacy study evaluating NUZYRA’s effectiveness in the treatment of pulmonary anthrax. In the study, a 100%
